Physician profile
Melody Smith
NPI 1790915031
$26,118.75
in general payments reported to CMS, 2019-2025
13 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2021: $4,290 · 2022: $1,783 · 2023: $19K · 2024: $456 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Food and Beverage: $1,041 · Consulting Fee: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $18,181.82 |
| Food and Beverage | $1,040.84 |
| Consulting Fee | $675.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $18,181.82 | 2023 | |
| Janssen Research & Development, LLC | $4,290.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,329.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $924.93 | 2022-2024 | Kymriah |
| Kite Pharma, INC. | $430.15 | 2022-2025 | Yescarta |
| Celgene Corporation | $254.75 | 2022-2024 | |
| Sobi, INC | $151.22 | 2024 | |
| Eli Lilly and Company | $148.07 | 2019 | |
| Incyte Corporation | $124.99 | 2022 | |
| Gilead Sciences, INC. | $120.83 | 2025 | Yescarta |
| National Marrow Donor Program | $75.00 | 2023 | |
| Abbott Laboratories | $64.92 | 2024 | Cardiomems |
| Adaptive Biotechnologies Corporation | $23.07 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.